Vericiguat bụ apyrazolopyridineya bu5-fluoro-1H-pyrazolo [3,4-b] pyridinenke amino hydrogen nọ n'ọkwa 1 jiri otu 2-fluorobenzyl dochie ya nahydrogenna ọnọdụ 3 ka 4,6-diamino-5-[(methoxycarbonyl) amino] pyrimidin-2-yl nọchiri anya ya.Ọ bụ ihe solubleguanylatecyclase stimulator nke a na-eji agwọ ọrịa obi na-adịghị ala ala.Ọ nwere ọrụ dị ka solubleguanylatecyclase activator, onye nnọchi anya vasodilator na onye nnọchi anya antihypertensive.Ọ bụ otuaminopyrimidine, apyrazolopyridine, ester carbamate na ogige organofluorine.

A na-enyocha Vericiguat na nyocha ụlọ ọgwụ NCT02861534 (A Ọmụmụ nke Vericiguat na ndị sonyere na nkụda mmụọ obi na mbelata ejection Fraction (HFrEF) (MK-1242-001)).

Vericiguat bụ SolubleGuanylateCyclase Stimulator.Usoro nke vericiguat dị ka aGuanylateCyclase Stimulator.

Vericiguat bụ ọgwụ eji ejikwa ma na-agwọ nkụda obi site na iji obere mbelata ejection (HFrEF).Ọ bara uru maka ọdịda obi na-akawanye njọ nke na-adịghị ala ala, nkụda mmụọ nke decompensated na nso nso a.Vericiguat anaghị agbatị ndụ mana ọ na-egbochi ibugharị ụlọ ọgwụ.Ihe omume a na-akọwapụta ihe ngosi, usoro omume, dose, na usoro nchịkwa nke otu ndị ọkachamara na-arụ ọrụ, mmetụta ọjọọ, contraindications, na ọtụtụ ule iji kwado ihe akaebe nke uru ọgwụ na HFrEF.